Clin2
NCT07347080Possibly a fitRecruiting

Study of a new RNA-based drug for type 2 diabetes

T2DM

Part of Hormones & metabolism clinical trials.

This trial tests an experimental injection (CR059) for type 2 diabetes. It looks at safety and how the body handles different doses. You may qualify if you have had diabetes for 3 months to 5 years and are currently managing it with diet/exercise or certain diabetes pills.

Summary written for real people, not researchers, by Clin2.

Phase
Early Phase 1
Enrollment
9 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • You must be Chinese and between 18 and 65 years old.
  • You must have had type 2 diabetes for at least 3 months but less than 5 years.
  • Your blood sugar is not well controlled with diet/exercise, metformin, or metformin combined with other oral diabetes drugs.
  • Your fasting blood sugar is below 13.0 mmol/L and your HbA1c is between 7.5% and 10.0%.
  • Your body mass index (BMI) is between 18.5 and 40.0.
  • You are not pregnant, plan to avoid pregnancy, and use effective contraception during and 3 months after the study.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06686134Recruiting
GLP-1 drug trial for type 2 diabetes

This trial tests a new GLP-1 receptor agonist to improve blood sugar control in people with type 2 diabetes. It may be an option if you haven't used a similar drug in the last three months and your medical records are complete.

Jinan
NCT07599410Recruiting· Phase 2
Testing HRS9531 for Type 2 Diabetes Blood Sugar Control

This study tests whether a new tablet called HRS9531 helps people with type 2 diabetes control their blood sugar better. You would take it along with your current diabetes management (lifestyle changes or metformin) over several months.

Beijing, Beijing Municipality
NCT07308184Not yet recruiting· Phase 3
Injectable study treatment for type 2 diabetes

This study tests an investigational injectable medicine (IN-B00009) to see how well it controls blood sugar in adults with type 2 diabetes that is not well managed by diet and exercise alone. If you qualify, you may receive the study drug and will be monitored closely to see if it helps lower your blood sugar safely.

NCT07156500Not yet recruiting· Phase 3
Investigational drug study for type 2 diabetes not controlled by diet and exercise

This study tests an investigational drug called HS-20094 to see how well it controls blood sugar in people with type 2 diabetes. It may help you manage your diabetes better if diet and exercise alone are not enough.

Beijing, Beijing Municipality
NCT06256419Recruiting
Gene testing and exenatide response in Chinese type 2 diabetes patients

This study looks at how certain genes affect the risk of type 2 diabetes and how well the drug exenatide (a GLP-1 receptor agonist) works in Chinese patients. It aims to see if your genetic makeup can predict how you will respond to treatment.

Xuzhou, China
NCT07156539Not yet recruiting· Phase 3
Study of a new medicine for type 2 diabetes

This study tests a new medicine called HS-20094 for people with type 2 diabetes. It aims to see if it helps lower blood sugar and may also help with weight. You may be able to join if you are currently on metformin or metformin plus an SGLT-2 inhibitor.

Jinan, Shandong

Hear when a new T2DM trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.